In addition, there are some limitations in the study, due to the lower incidence of male breast cancer, the included sample size is small, but the inclusion of female breast cancer in the same period as a control group better reflects the clinicopathological characteristics of HER2 low-expression male breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.